<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02699008</url>
  </required_header>
  <id_info>
    <org_study_id>PFT-2015-01</org_study_id>
    <nct_id>NCT02699008</nct_id>
  </id_info>
  <brief_title>High On-treatment Platelet Reactivity Identified by Multiple Platelet Function Assay</brief_title>
  <acronym>HOPEmultiPFA</acronym>
  <official_title>High On-treatment Platelet Reactivity to Adenosine Diphosphate Identified by Multiple Platelet Function Assay Guide to Modify Anti-platelet Strategy in Patients Undergoing Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuhan Asia Heart Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wuhan Asia Heart Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      High on-treatment platelet reactivity to adenosine diphosphate was a important reason to
      cause ischemic events in antiplatelet therapy. Using single testing to definite HPR may miss
      the &quot;true HPR&quot; or over estimate HPR, which may lead to randomized trials failed. It is not
      known whether combined multiple platelet function testing could assist to ensure&quot;ture&quot;HPR and
      improve clinical outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a single-center, randomized, prospective study. ACS patients undergoing PCI treated
      with clopidogrel and aspirin were included. in the 3-5th day after prescription of
      clopidogrel, platelet function were tested simultaneously by three methods: MPAADP by Light
      transmittance aggregometry（LTA）, MAADP by Thrombelastography (TEG) ,and CTP2Y by Innovance
      PFA-200 . According to three result（Two of three or all three results higher than cutoff
      value was identified as HPR, MPALTA&gt;50%;MAADP&gt;47mm;CTP2Y&lt;106s）.Patients was defined as
      HPR(n=125) or unHPR(n=232), HPR patients were divided into HPR-Ticagrelor(HPR-T)and
      HPR-Clopidogrel(HPR-C) randomized. HPR-T group(n=77) patients' antiplatelet agents changed to
      ticagrelor, both unHPR and HPR-C groups keep unchanged(Clopidogrel). The major adverse
      cardiovascular events (MACE) were recorded during 1 year Follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major adverse cardiovascular events</measure>
    <time_frame>1 year</time_frame>
    <description>stent thrombosis；ACS；all cause Death；stroke；</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding events</measure>
    <time_frame>1 year</time_frame>
    <description>gastrointestinal bleeding；gastrointestinal bleeding；other bleeding need RBC transfusion</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">477</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>HPR-Ticagrelor row</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ACS patients aftergoing PCI treated with clopidogrel and aspirin were included. in the 3-5th day after prescription of clopidogrel, platelet function were tested simultaneously by three methods: Light transmittance aggregometry（LTA）, Thrombelastography (TEG) ,Innovance PFA-200 . According to three method results（Two of three or all three results higher than cutoff value was identified as HPR, MPALTA&gt;50%;MAADP&gt;47mm;CTP2Y&lt;106s）.Patients was defined as HPR and unHPR, HPR patients were randomized divided into HPR-Ticagrelor(HPR-T) and HPR-Clopidogrel(HPR-C)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HPR-Clopidogrel row</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Thrombelastography (TEG) ,Innovance PFA-200 . According to three method results（Two of three or all three results higher than cutoff value was identified as HPR, MPALTA&gt;50%;MAADP&gt;47mm;CTP2Y&lt;106s）.Patients was defined as HPR and unHPR, HPR patients were randomized divided into HPR-Ticagrelor(HPR-T) and HPR-Clopidogrel(HPR-C)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>unHPR row</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Thrombelastography (TEG) ,Innovance PFA-200 . According to three method results（Two of three or all three results higher than cutoff value was identified as HPR, MPALTA&gt;50%;MAADP&gt;47mm;CTP2Y&lt;106s）.Patients was defined as HPR and unHPR, HPR patients were randomized divided into HPR-Ticagrelor(HPR-T) and HPR-Clopidogrel(HPR-C)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Antiplatelet agent</description>
    <arm_group_label>HPR-Clopidogrel row</arm_group_label>
    <arm_group_label>unHPR row</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>New P2Y12 receptor inhibitor antiplatelet agent</description>
    <arm_group_label>HPR-Ticagrelor row</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ACS patients（UAP;USTEMI,STEMI）

          -  Undergoing PCI

          -  Oral antiplatelet therapy

        Exclusion Criteria:

          -  Stable CAD
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhou xin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Wuhan Asia Heart Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wuhan Asia Heart Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2015</study_first_submitted>
  <study_first_submitted_qc>February 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2016</study_first_posted>
  <last_update_submitted>February 29, 2016</last_update_submitted>
  <last_update_submitted_qc>February 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>clopidogrel；antiplatelet therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

